Understand · Treat · Recover
Genetic Testing and Molecular Biomarkers
Inherited testing and tumour testing answer related but different questions.
This guide is educational and does not replace individual medical assessment. Do not start, stop or change treatment without the treating team. Cancer Aware supports patients and families worldwide. Drug approvals, availability, affordability and care pathways vary by country.
Chapter 7 of 20
Germline versus tumour testing
Germline testing usually uses blood or saliva to look for inherited variants that may affect relatives as well as treatment. Somatic testing studies tumour changes, which may be acquired rather than inherited. People with epithelial ovarian cancer should be offered germline assessment even without family history. Tumour testing can add information when germline BRCA testing is negative. Genetic counselling explains implications and consent.
The main results to discuss
| Test | Question it helps answer |
|---|---|
| BRCA1 / BRCA2 | Could DNA-repair biology influence treatment and inherited risk? |
| HRD | Does the tumour show a broader pattern of impaired DNA repair relevant to selected maintenance choices? |
| MMR / MSI | Could a repair defect support selected immunotherapy or hereditary assessment? |
| FRα | Could an antibody–drug conjugate be suitable in an eligible recurrent setting? |
| PD-L1 CPS | Could a specific immunotherapy combination fit an approved recurrent-disease indication? |
| KRAS in low-grade serous cancer | Could a molecularly selected targeted treatment be relevant? |
IHC is not the same as sequencing
Immunohistochemistry (IHC) measures proteins in tissue and is used for markers such as MMR proteins, FRα and PD-L1. DNA sequencing detects genetic changes; HRD assays use their own methods and thresholds. One broad sequencing test does not necessarily replace every protein-based companion test. Ask which tests change a decision now.
Avoid overinterpreting a result
HRD-positive does not automatically mean hereditary cancer. A variant of uncertain significance (VUS) is not a confirmed harmful variant and should not by itself trigger preventive surgery or family predictive testing. A negative result does not guarantee zero risk or response to treatment. Relatives should receive counselling and targeted testing when a relevant inherited pathogenic variant is confirmed.
Key takeaway
Ask what each result changes for treatment and separately for the family.
Common questions
Is BRCA testing useful without affected relatives?
Yes. Epithelial ovarian cancer itself is a reason to discuss germline testing.
Does a tumour BRCA result prove inheritance?
No. A separate germline assessment may be needed.
Does HRD guarantee a PARP inhibitor will work?
No. It helps estimate likely benefit within a defined clinical setting.
Does a VUS mean preventive surgery is needed?
Not on that finding alone.
Should children be tested immediately?
Timing depends on the gene and whether childhood management changes; seek genetics advice rather than testing automatically.